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Background: Pancreatic cancer is a lethal disease due to the high incidence of metastasis at the time of detection.
CD133 expression in clinical pancreatic cancer correlates with poor prognosis and metastasis. However, the molecular
mechanism of CD133-regulated metastasis remains unclear. In recent years, epithelial-mesenchymal transition (EMT) has
been linked to cancer invasion and metastasis. In the present study we investigated the role of CD133 in pancreatic
cancer metastasis and its potential regulatory network.
Methods: A highly migratory pancreatic cancer cell line, Capan1M9, was established previously. After shRNA was stable
transducted to knock down CD133 in Capan1M9 cells, gene expression was profiled by DNA microarray. Orthotopic,
splenic and intravenous transplantation mouse models were set up to examine the tumorigenesis and metastatic
capabilities of these cells. In further experiments, real-time RT-PCR, Western blot and co-immunoprecipitate were
conducted to evaluate the interactions of CD133, Slug, N-cadherin, ERK1/2 and SRC.
Results: We found that CD133+ human pancreatic cancer cells were prone to generating metastatic nodules in in vivo
models using immunodeficient mice. In contrast, CD133 knockdown suppressed cancer invasion and metastasis in vivo.
Gene profiling analysis suggested that CD133 modulated mesenchymal characteristics including the expression of
EMT-related genes, such as Slug and N-cadherin. These genes were down-regulated following CD133 knockdown.
Moreover, CD133 expression could be modulated by the extracellular signal-regulated kinase (ERK)1/2 and SRC signaling
pathways. The binding of CD133 to ERK1/2 and SRC acts as an indispensable mediator of N-cadherin expression.
Conclusions: These results demonstrate that CD133 plays a critical role in facilitating the EMT regulatory loop,
specifically by upregulating N-cadherin expression, leading to the invasion and metastasis of pancreatic cancer cells.
Our study provides a novel insight into the function of CD133 in the EMT program and a better understanding of the
mechanism underlying the involvement of CD133 in pancreatic cancer metastasis.
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Pancreatic ductal adenocarcinoma (PDAC) is a lethal dis-
ease due to the high occurrence of metastasis at the time of
detection [1]. The poor prognosis of patients with PDAC
has been attributed to early vascular dissemination and
metastasis to distant organs, particularly the liver, lungs,
and peritoneum. Accumulating evidence has shown that
the increased motility and invasiveness of cancer cells are* Correspondence: sonshin@m2.kufm.kagoshima-u.ac.jp
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stated.associated with epithelial-mesenchymal transition (EMT)
[2]. EMT is a cellular program that governs morphogenesis
and is activated during embryogenesis. EMT transcription
factors mediate the conversion of polarized immotile
epithelial cells into mobile mesenchymal progenitor cells,
which can facilitate cancer cell migration and invasion.
Several groups have reported that EMT also contributes
to the properties of cancer stem cells (CSCs) [3-5]. For
example, Mani et al. demonstrated that immortalized
human mammary epithelial cells undergoing EMT not
only resulted in the acquisition of mesenchymal traits but
also expressed stem cell markers and acquired the properties
associated with mammary epithelial stem cells [5].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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initiation, invasion, and metastatic spread and an increase
in tumor stemness. The primary molecular feature of
carcinoma EMT is the upregulation of characteristic
mesenchymal genes, including N-cadherin, fibronectin,
snail1, and snail2 (Slug). EGF signaling pathways are also
potent inducers of the EMT program [6], and EGF can
activate several pathways through its receptor. The two
major intracellular pathways activated by EGFR are the
RAS-RAF-MEK-MAPK-ERK pathway and the PI3K-Akt
pathway [7].
Oncogenic Kras is the initiating mutation in nearly all
PDACs. The Ras-ERK pathway is involved in subsequent
malignant proliferation, migration, and invasion. According
to reports, most PDACs also have elevated SRC activity [8].
CD133 and SRC kinase have recently been shown to play
roles in the regulation of tumor-initiating properties and
the EMT program of head and neck carcinoma cells [9]. As
SRC is a classical non-receptor tyrosine kinase with the
potential to cause cell transformation, CD133 may play an
important role in the regulation of SRC function by acting
as a substrate for SRC family tyrosine kinases [9,10].
The transmembrane protein CD133 (also known as
prominin-1 or AC133) is of particular interest and a
subject of much debate. CD133 is the most commonly
expressed CSC marker in several cancer types, including
pancreatic cancer. It has been reported that CD133+ cells
are the dominant cell population in primary non-small cell
lung cancer and that these cells have greater tumorigenic
potential in severe combined immunodeficient (SCID) mice
and greater involvement in stemness, adhesion, and
motility in comparison to their CD133- counterparts
[11]. However, the biological function of CD133 in the
metastasis of solid carcinomas is still unknown.
We have previously reported a significant correlation
between CD133 expression and clinicopathologic factors,
histological type, lymphatic invasion, and lymph node
metastasis in a cohort of pancreatic cancer patients who
underwent curative surgery [12]. We were specifically able
to select a subclone from a pancreatic cancer cell line that
reflected aggressive migratory behavior and high CD133
expression. CD133 plays a regulatory role in the expression
of Slug, which is one of the major EMT transcription
factors [13]. These results strongly imply that CD133
participates in the regulatory network to facilitate EMT.
The goal of the present study was to unravel the molecu-
lar mechanisms involved in the regulatory association
between EMT and CD133 in the interaction network.
Results and discussion
CD133 contributes to hematogenous metastasis in vivo
In our previous study, we reported that a highly migratory
subclone, Capan1M9, derived from the human pancreatic
cancer cell line, Capan-1, exhibited a high level of CD133expression (Additional file 1: Figure S1). The migratory
ability of these cells was suppressed by knockdown of
CD133 expression with shRNA in vitro [13]. To investigate
the different capabilities of CD133high (Capan1M9) and
CD133knockdown (KD) (shCD133M9) cells in tumorigenesis
and metastasis, we established an orthotopic pancreatic
tumor model to examine local invasion and a hemato-
genous lung or liver metastasis model using BALB/c nude
mice. More specifically, a dose of 2× 105 Capan1M9 or
shCD133M9 cells was injected into nude mice. Following
injection into the pancreas, spleen, or tail vein, the mice
were sacrificed at 4, 4, or 16 weeks after cell implantation,
respectively (Additional file 1: Figure S2). As determined by
hematoxylin and eosin (HE) staining, the tumors generated
by Capan1M9 and shCD133M9 cells in the pancreas with
cell morphology analogous to that of PDAC (Figure 1A).
Moreover, the tumors generated by Capan1M9 cells also
exhibited CD133-positive staining and an invasive and
aggressive growth pattern. Many cancer lesions were ob-
served invading the surrounding normal tissue, showing an
intensive interaction with the stromal tissues (Figure 1A, top
right). In contrast, the tumors generated by shCD133M9
cells exhibited CD133-negative staining and an expansive
growth pattern with a clear margin between the tumor
and surrounding stromal tissues (Figure 1A, bottom right).
Moreover, five (62.5%) of the eight mice intravenously
injected with Capan1M9 cells developed metastatic nod-
ules in the lungs in comparison to one (10%) of the ten
mice injected with shCD133M9 cells (Figure 1B, Figure 1D
and Additional file 1: Figure S3). In the liver, seven (78%)
of nine mice with splenic implantation of Capan1M9 cells
generated metastatic nodules compared to one (12.5%) of
eight mice injected with shCD133M9 cells (Figure 1C and
Figure 1D). However, there was no significant difference of
subcutaneously tumor-take rates between CD133high and
CD133KD cells and the growth rates between the tumors
generated by CD133high and CD133KD cells (Additional
file 1: Figure S4 and S5). Moreover there was no significant
difference of the tumor volumes between the tumors
generated by CD133high and CD133KD cells in orthotopic
tumor model after four weeks (Additional file 1: Figure S6).
Execution of metastasis is composed of multiple processes
including cancer cell detachment from the primary tumor,
local invasion to disseminate through surrounding blood
vessels or lymphatic vessels, and attachment and prolifera-
tion at the metastatic site. In our study, it is thought that
CD133 contributes to the cancer cell survival in circulation,
extravasation, colonization in the distant organ and forma-
tion of macro metastasis, which are essential for the process
of cancer metastasis. It is also notable that there was no sig-
nificant difference of the tumorigenesis capability between
Capan1M9 and shCD133M9 cells. These results indicated
that CD133 plays a critical role in tumor invasiveness and
metastasis, but little role in tumorigenesis.
Figure 1 CD133+ pancreatic cancer cells were prone to generating metastatic nodules in in vivo models using immunodeficient mice.
(A) Tumor morphologies (left) and CD133 immunohistological staining (right) of these tumors, which were observed in the pancreas at 4 weeks after
the orthotopic implantation of Capan1M9 (CD133high) or shCD133M9 (CD133KD) cells. (B) Macro-metastatic nodules were observed in the lungs 16
weeks after the intravenous injection of Capan1M9 cells into the tail vein (left). The nodule was barely visible after the injection of shCD133M9 cells
(right). (C) Macro-metastatic nodules observed in the liver at 4 weeks after the splenic implantation of Capan1M9 cells (left). In contrast, the metastatic
nodule was barely visible after the implantation of shCD133M9 cells (right). (D) Statistical analysis of the number of macro-metastatic nodules generated
in the lungs or liver after intravenous or splenic implantation showed that Capan1M9 cells were prone to generating metastases in comparison with
shCD133M9 cells. Each mouse received 2 × 105 cells of Capan1M9 or shCD133M9 in these experiments.
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To gain a genome-wide understanding of CD133-related
gene expression in the highly migratory PDAC cells, we
performed global gene-expression profiling in Capan1M9
and shCD133M9 cells. We used and improved an unbiased
algorithm developed by Cheadle et al. [14] to assess
whether a particular gene set was statistically over- or
under-expressed in a given mRNA transcript expression
profile. Briefly, we calculated Z-scores for each gene in a
given expression profile, assuming that these expression
values have a normal distribution to minimize the noise
arising from different expression profiles obtained across
diverse platforms. Microarray analyses indicated that the
knockdown of CD133 led to a reduction in several
molecular features of EMT. The profile of Capan1M9
(CD133high) or shCD133M9 cells (CD133KD) was clus-
tered into two separate subgroups, as shown in
Figure 2A and Additional file 2: Table S1. Slug, N-
cadherin, and fibronectin, which are characteristic compo-
nents of mesenchymal cells, were downregulated in the
CD133KD cells (Figure 2B and Additional file 2: Table
S2). In contrast, E-cadherin, desmoplakin, and occludin,
which are characteristic components of epithelial cells,showed no significant changes after CD133 knockdown.
These findings were confirmed by real-time RT-PCR and
Western blot analysis (Figure 2C and Figure 2D). Based
on the above analysis and results, despite CD133 knock-
down, shCD133M9 cells could still generate tumors in the
orthotopic mouse models, suggesting that the epithelial
phenotype plays the dominant role in tumorigenesis. This
suggests that only cells possessing mesenchymal traits can
infiltrate into the stroma, invade, and disseminate to dis-
tant organs. Gene profiling analysis suggested that
CD133 might be a regulator of mesenchymal markers.
Evidence shows that during EMT, the activity of adherent
junctions is highly modified, primarily because E-cadherin
is replaced or overruled by N-cadherin in a process called
“cadherin switching” [15]. Our data implied that N-cadherin
has the dominant effect in these cell-cell interactions, even
in the presence of E-cadherin. Over-expressed N-cadherin
may disrupt the intercellular adhesion complexes and
result in the epithelial cell losing the apical-basal polarity.
These changes enable the epithelial cells to assume a
mesenchymal phenotype and to enhance the motility of
tumor. It is so-called the initial EMT program. CD133 is a
transmembrane protein, which location is well suited for a
Figure 2 CD133 acts as a regulator of the mesenchymal phenotype. (A) A heatmap of the DNA microarray demonstrates the distinct
molecular profiles of Capan1M9 and shCD133M9 cells. (B) A heatmap of EMT-related genes with a Z-score greater than 2 distinguished between
Capan1M9 and shCD133M9 cells. (C) Validation of the levels of the EMT-related proteins fibronectin, N-cadherin, and E-cadherin in Capan1M9
and shCD133M9 cells by Western blot. (D) Validation of EMT-related genes in Capan1M9 with shCD133M9 cells by real-time RT-PCR.
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regulating the EMT program, particularly the “cadherin
switch”.
CD133 and Slug regulate the N-cadherin expression
required for migration and invasion
Reports have demonstrated that N-cadherin can promote
motility, invasion, and metastasis in breast cancer, even in
the presence of E-cadherin [15]. To investigate the role
of N-cadherin in PDAC cell migration and invasion,
Capan1M9 was treated with an N-cadherin-neutralizing
antibody, and a wound healing assay was performed. After
the N-cadherin-neutralizing antibody was introduced, the
wound healing speed was significantly slower than that
without antibody neutralization. The healing area in
the antibody-treated group was half of that without
neutralization (Figure 3A and Figure 3B). To investigate
whether CD133 and Slug could regulate N-cadherin ex-
pression in pancreatic cancer during migration and in-
vasion, shRNA was transduced into Capan1M9 cells to
knockdown Slug or CD133. Real-time RT-PCR was used
to validate the efficiency after transduction. The expres-
sion levels of Slug and CD133 were reduced by 70% and
60%, respectively (Additional file 1: Figure S7). The mRNAand protein expression levels of N-cadherin were deter-
mined by real-time RT-PCR and Western blot analysis,
respectively, after shRNA transduction of CD133 or Slug.
N-cadherin mRNA expression was decreased by greater
than 95% and 60% after CD133 and Slug knockdown,
respectively (Figure 3D). N-cadherin protein expression
was also significantly decreased after CD133 or Slug
knockdown (Figure 3C). In addition, the Slug expres-
sion level was reduced after CD133 knockdown,
whereas the CD133 expression level did not change
after Slug knockdown (Figure 3C).
To further confirm that CD133 plays roles in regulating
N-cadherin and in PDAC migration and invasion, we
overexpressed CD133 by transducing His-CD133 into
Capan1M9 cells using lentiviral vectors. CD133 expression
was upregulated following transduction as well as the
N-cadherin expression level (Figure 3E). To exclude cell
line-specific effects, we also overexpressed CD133 in Panc-
1 cells with only 1.3% of CD133 expression. N-cadherin
upregulation was detected in the His-CD133-transduced
Panc-1 cells, consistent with the results obtained using
Capan1M9 cells (Figure 3E).
These data indicate that the inhibition of N-cadherin
alone could suppress the migratory ability of pancreatic
Figure 3 CD133 and Slug regulate N-cadherin expression, which is required for migration and invasion. (A) A wound healing assay
showed that the healing speed decreased after N-cadherin neutralization using an antibody. (B) Statistical analysis of the mean healed area demonstrated
significant differences between with and without N-cadherin antibody neutralization at 12 h (p < 0.05) and 24 h (p < 0.01). (C) N-cadherin mRNA
expression decreased by greater than 95% and 60% after CD133 and Slug knockdown, respectively, validated by real-time RT-PCR. (D) N-cadherin
protein expression decreased after CD133 or Slug knockdown, as shown by Western blotting. (E) N-cadherin protein expression increased after CD133
was overexpressed in Capan1M9 cells and Panc-1 cells, as shown by Western blot analysis.
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loss of E-cadherin expression and overexpression of
N-cadherin, which indicate the presence of EMT, are
independently correlated with a high Gleason score and
systemic and metastatic recurrence after surgery. This
finding links EMT to more aggressive clinical behavior
[16]. In breast cancer, a similar link has been established
between EMT markers in primary and disseminated
bone marrow tumor cells and aggressive clinical behavior
[17]. Furthermore, in liver cancer cell lines, CD133+ cells
showed upregulated N-cadherin expression and down-
regulated E-cadherin expression compared with CD133-
negative cells, which suggest that EMT more commonly
occurs in CD133-positive cells than in CD133-negative
cells [18]. The present study indicates that CD133 plays an
important role in N-cadherin expression, and regulates
Slug expression. Furthermore, Slug could regulate N-
cadherin expression. However, there might be other
molecules involved with CD133 in the regulation of the
expression of Slug, which is a transcription factor. Further
study is needed to clarify this regulation loop. It infers
that CD133 may be a critical mediator facilitating EMT,
primarily through Slug and N-cadherin regulation.The MAPK/ERK and SRC pathways underlie
CD133 expression
The MAPK/ERK pathway is a chain of proteins within cells,
and it communicates a signal from a cell surface receptor
to the DNA in the nucleus. The signal starts when a signal-
ing molecule binds to the cell surface receptor and ends
when the DNA in the nucleus expresses a protein that
induces a certain change in the cell, such as cell division.
The pathway includes many proteins, including MAPK
(originally called ERK). Components of the MAPK/ERK
pathway were initially discovered in many solid cancers,
including PDAC [19,20]. ERK1/2 is the primary mediator
among these components and is stimulated by EGF. It
has also been shown that CD133 can be phosphorylated
by SRC to activate its function [9]. To unravel the CD133-
related signaling pathway in EMT regulation, we examined
the effects of the classical EMT-inducing factors TGF and
EGF on Slug and N-cadherin expression. Capan1M9 cells
were exposed to TGF and the ERK1/2 inhibitors, SB431542
and U1026, and the expression of Slug and N-cadherin was
examined. Compared with TGF inhibitor treatment, the
ERK1/2 inhibitor showed a more powerful potential to
decrease the expression of Slug and N-cadherin (Additional
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be the dominant factor triggering EMT in Capan1M9
cells. To investigate the relationship between ERK, SRC,
and CD133, we examined the expression levels of
phosphorylated ERK (p-ERK) and phosphorylated SRC
(p-SRC) before and after CD133 knockdown. Western
blot analysis detected no alteration after CD133 or Slug
knockdown (Figure 4A). We then treated Capan1M9
cells with U0126 or a SRC inhibitor, and the mRNA and
protein expression levels were examined. The mRNA
levels of CD133 and Slug were reduced after the cells were
treated with ERK inhibitor (U0126) for 48 h (Figure 4B).
Additionally, CD133 protein expression was dynamically
decreased in a time-dependent manner when cells were
treated with ERK or SRC inhibitor (Figure 4C and
Figure 4D).
The expression levels of p-ERK and p-SRC did not
change significantly after CD133 or Slug knockdown,
which suggested that the ERK or SRC pathway might be
located upstream of the CD133 and Slug regulation loop.
According to one report, CD133 expressed endogenously
or exogenously in medulloblastoma cells is phosphory-
lated by SRC and Fyn, two members of the SRC-family
tyrosine kinases [9]. In our study, CD133 expression in
Capan1M9 cells was downregulated by a SRC inhibitor.
Kemper et al. defined that a relationship between theFigure 4 The MAPK/ERK/SRC pathway underlies CD133 expression. (A
detected inCapan1M9, shCD133M9 or shSlugM9 cells. (B) CD133 and Slug
results were validated by real-time RT-PCR. (C) CD133 protein expression d
shown by Western blot analysis. (D) CD133 protein expression decreased d
Western blot analysis.hyper-activation of the Ras-Raf-MEK-ERK pathway can
regulate CD133 expression, and mutations of either gene
have been associated with a poor prognosis [21]. Our
study is consistent with these reports and reveals the
associations between ERK, SRC, and CD133.
The ERK/SRC/CD133 axis as an indispensable complex
regulating N-cadherin
We found that CD133 could regulate Slug to facilitate
EMT and regulate N-cadherin expression and that ERK
and SRC could regulate CD133 expression. These findings
raised the question of whether a network exists between
ERK, SRC, and CD133 that is associated with N-cadherin
regulation. We first examined N-cadherin expression after
U0126 or SRC inhibitor treatment. A time-dependent
decrease in N-cadherin expression was observed after these
treatments in Capan1M9 cells (Figure 5A and Figure 5B).
Further, we examined EGF stimulation of N-cadherin
expression in shCD133M9 and shSlugM9 cells. The level
of N-cadherin expression after EGF treatment did not
increase in CD133KD cells; on the contrary, it was increased
in shSlugM9 cells (Figure 5C). A co-immunoprecipitation
experiment was performed to unravel the relationship
between CD133, ERK, and SRC. CD133-His was trans-
duced into Capan1M9 cells, and we used an anti-His
antibody to immunoprecipitate the cell lysate. CD133,) No alteration of the protein expression levels of pERK and pSRC was
expression decreased after ERK1/2 inhibitor (10 μg/mL) treatment;
ecreased drastically after ERK1/2 inhibitor (10 μg/mL) treatment, as
ynamically after SRC inhibitor (10 μg/mL) treatment, as shown by
Figure 5 ERK/SRC/CD133 is an indispensable complex for the regulation of N-cadherin. (A) N-cadherin expression decreased dynamically
after ERK1/2 inhibitor (10 μg/mL) treatment in Capan1M9 cells, as shown by Western blot analysis. (B) N-cadherin expression decreased dynamically
after SRC inhibitor (10 μg/mL) treatment in Capan1M9 cells, as shown by Western blot analysis. (C) N-cadherin expression did not increase following
EGF (10 μg/mL) treatment in shCD133M9 cells, although it did increase in shSlugM9 cells following EGF (10 μg/mL) treatment, as shown by Western
blot analysis. (D) After transducing His-CD133 into Panc-1 and Capan1M9 cells, anti-His immunoprecipitates (IPs) were probed with anti-ERK1/2,
anti-SRC, and anti-CD133 antibodies. IB, immunoblotting. (E) Hypothetical scheme of the CD133/ERK/N-cadherin regulation loop in pancreatic cancer
metastasis. CD133 expression was upregulated, and CD133 combined with ERK and SRC to form a regulation complex that was indispensable for EGF
activation of the ERK pathway and subsequent N-cadherin expression. CD133 acts as a mesenchymal mediator to facilitate the EMT program.
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and p-SRC (tyr416) were detected in the eluate from
the immunoprecipitated His (Figure 5D). ERK1/2 is the
primary mediator among the MAPK/MEK pathway com-
ponents. Our observation revealed that CD133 is bound
to ERK and SRC.
The preferential localization of CD133 to plasma mem-
brane protrusions [22] and its ability to specifically
interact with plasma-membrane cholesterol in cholesterol-
based lipid rafts suggest the involvement of CD133 in the
regulation of plasma membrane topology. To establish
and maintain membrane protrusions, CD133 may be
involved in cell polarity and migration [22] via cell-cell
and cell-extracellular matrix interactions [23]. According
to many reports, EGF is the dominant factor that increases
N-cadherin levels [21,24]. Upregulation of N-cadherin wasobserved in shSlugM9 cells following EGF treatment,
but knockdown of CD133 abolished the ability of EGF
to induce N-cadherin expression (Figure 5C). These data
indicate that CD133 is an indispensable mediator of N-
cadherin expression (Figure 5E).
Conclusions
Wei and colleagues have recently reported that the
CD133/PI3K/Akt signaling axis regulates glioma stem cell
behavior, self-renewal, and tumorigenesis, as SRC binds to
the cytoplasmic tail of CD133 and consequently activates
the PI3K/Akt pathway [25]. CD133 expression could be
upregulated by activated ERK and SRC, and form a
CD133/ERK/SRC complex, which is necessary for EGF
to activate the downstream ERK pathway and induce
N-cadherin expression and facilitate the EMT program
Ding et al. Molecular Cancer 2014, 13:15 Page 8 of 11
http://www.molecular-cancer.com/content/13/1/15(Figure 5E). The presence of the CD133/ERK/SRC signal-
ing axis indicates that CD133 acts as a characteristic
mesenchymal regulator and is a “functional” marker of
migration, invasion, and metastasis in pancreatic cancer.
Therefore, CD133 plays a critical role in survival of pancre-
atic cancer cells in the circulation system, extravasation,
and colonization in the metastatic sites. Our study provides
novel insight into the interaction between CSCs and the
EMT program and a better understanding of the mechan-
ism underlying the involvement of CD133 in cancer metas-
tasis. Furthermore, our study may facilitate the discovery of
a novel targeted therapy and diagnostic tool for PDAC.Methods
Cells and reagents
The human pancreatic cancer cell lines Capan-1 and
Panc-1 were purchased from the American Type Culture
Collection (ATCC, VA, USA). A highly migratory subclone
cell line, Capan1M9, was established from the Capan-1 as
previous reported [13]. EGF, an ERK1/2 inhibitor (U0126),
a SRC inhibitor-1, and a TGF inhibitor (SB431542) were
used at a working concentration of 10 μg/mL; all were
purchased from Sigma-Aldrich Co. (St. Louis, MO, USA).Animal studies
Male BALB/c nude mice aged 8 to 10 weeks were pur-
chased from Crea Japan Co. Ltd. (Tokyo, Japan).
1. Orthotopic and metastatic mice models:
To create an orthotopic tumor model in the pancreas
and a liver or pulmonary metastasis model, tumor cells
were implanted into the pancreas, spleen, or lateral tail
vein via a 27-gauge needle under anesthesia, which was
induced by the inhalation of 1-chloro-2,2,2-trifluoroethyl
difluoromethyl ether (Isoflurane). The mice were immo-
bilized in a restraining device. Tumor cell implantations
were performed using freshly prepared suspensions at a
concentration of 2 × 106 tumor cells/mL, and 2 × 105
tumor cells were implanted into each nude mouse. The
design of the mouse experiment is shown in Additional
file 1: Figure S2. After implantation, mouse body weight
was measured once a week. The nude mice were sacrificed
4 weeks after pancreas or spleen implantation or 16 weeks
after tail vein injection. Organs, including the liver,
pancreas, and lungs, were fixed in formalin for standard
paraffin embedding. The resultant 3-μm paraffin sections
were fixed and stained with hematoxylin-eosin (HE).
2. Subcutaneously xenograft mice model
1× 102 or 1× 103 tumors cells were inoculated subcuta-
neously at the flanks of mice (Additional file 1: Figure S4).Tumor size was monitored twice a week after the visible
tumor nodules appeared.
All animal experiments were approved by the Commit-
tee on the Use of Live Animals for Teaching and Research
and conducted in accordance with the Animal Care and
Use Committee guidelines of Kagoshima University.
Wound healing assay
A CytoSelect™ 24-well wound healing assay (Cell Biolabs,
CA, USA) was used as a migration assay. A wound field
was generated according to the product manual. A cell
suspension was added to the well, with the insert in
place, and then incubated for 24–48 h. Next, the cells
were cultured until a monolayer formed, and the insert
was removed to generate a “wound field”. The cells were
then monitored under a microscope to examine migration
into the wound field until the wound closed. The wound
healing area was calculated using the software AxioVision-
Rel (Zeiss, Germany).
Immunohistochemical staining
Five consecutive 3-μm histological sections of the mouse
tissues were stained with either HE, mouse monoclonal
GFP antibody (Novus Biologicals, Littleton, USA), mono-
clonal mouse anti-human pan-cytokeratin (CK) (Dako,
Carpinteria, CA, USA) or CD133/1 (AC133) (Miltenyi-
Biotec, Bergisch Gladbach, Germany). Briefly, after the
3-μm sections were deparaffinized and endogenous perox-
idases were blocked, the sections were incubated at 4°C
overnight with each antibody. The sections were incu-
bated for 30 min with biotinylated anti-mouse IgG in
PBS at room temperature. After being washed, the sec-
tions were incubated for 30 min with avidin and a bio-
tinylated horseradish peroxidase complex, and immune
complexes were visualized by incubating the sections
with 3,3’-diaminobenzidine tetrahydrochloride (DAB) or
PermaRed/AP (Diagnostic BioSystems, Pleasanton, CA,
USA). Images were captured with an Olympus micro-
scope. PBS was substituted for the primary antibody in
the negative-control group.
Cell lysates and immunoblotting
Cells were lysed on ice in lysis buffer. The lysates were
then boiled for 5 min, clarified by centrifugation at
15,000 × g for 15 min, and separated by SDS-PAGE. The
proteins were then transferred onto nitrocellulose mem-
branes, which were incubated with a 1:100–200 dilution
of human polyclonal or monoclonal antibodies raised
against the following: E-cadherin, N-cadherin, pERK,
ERK (Santa Cruz, CA, USA), fibronectin(R&D, MN,
USA), CD133 (MiltenyiBiotec, Germany), and pSRC
(CST, MA, USA). Next, a 1:200–1000 dilution of peroxidase-
conjugated anti-goat IgG, anti-rabbit IgG (Santa Cruz, CA,
USA), or anti-mouse IgG (Jackson ImmunoResearch, PA,
Ding et al. Molecular Cancer 2014, 13:15 Page 9 of 11
http://www.molecular-cancer.com/content/13/1/15USA) antibody was applied for the secondary reaction. As
an internal control for protein loading, β-actin was de-
tected using a specific antibody (Sigma, MO, USA). Im-
mune complexes were visualized using the ECL Western
blotting detection system (Amersham, UK).
shRNA and His-tag transfection
The Capan1M9-GFP-shRNA CD133 cell line was estab-
lished as previously described [13]. The Capan1M9-GFP-
shSlug cell line was established by lentiviral transduction.
pLVTHM is a second-generation lentiviral vector that
engineers shRNA under an H1 promoter (Addgene, MA,
USA) and co-expresses enGFP under the elongation factor
1a promoter. Slug shRNA sense (5’-cgcgtcccccagacccattct
gatgtaaagttcaagagactttacatcagaatgggtctgtttttggaaat-3’) and
Slug shRNA antisense (5’-cgatttccaaaaacagacccattctgatg
taaagtctcttgaactttacatcagaatgggtctggggga-3’) oligonucle-
otides were annealed to each other and ligated into the
pLVTHM vector at the ClaI and MluI sites, which yielded
the pLVTHM-Slug shRNA transfer vector. C-terminally
His-tagged CD133 expressing the lentiviral vector was
constructed by replacing the pDY.LNGFRTmpk lentiviral
vector (2) with CD133-His cDNA. Briefly, CD133 cDNA
was amplified with primer 1 (5’-GGTACCGCGGGCG
CGCCATGGCCCTCGTACTCGGCTC-3’) and primer 2
(5’-ATTGAAGCTTGGATCCTCAGTGATGGTGATGG
TGATGATGTTGTGATGGGCTTGTCA-3’) to add a His
tag. The resultant amplicon was ligated into the pDY.
LNGFRTmpk lentiviral vector by replacing TmpkcDNA
with CD133-His cDNA using an In-Fusion HD Cloning
Kit (Clontech, Mountain View, CA), generating the pDY.
LNGFR CD133-His lentiviral vector. Next, 293 T cells
were co-transfected with 4 μg of transfer plasmid, 3 μg of
psPAX2 packaging plasmid, and 1 μg of pMD2. G envelope
plasmid using FuGene 6 transfection reagent (Roche, CA,
USA). Twenty-four hours after transfection, the medium
was replaced with fresh DMEM with10% FBS. Forty-eight
hours after transfection, the viral supernatant was harvested
and filtered through a 0.45-μm filter. Capan1M9 cells
were then transduced with filtered viral supernatant
containing 8 μg/mL protamine sulfate for 72 h after
transfection. Flow cytometry analysis of enGFP expression
was performed with a FACS can (BD Biosciences, CA,
USA). enGFP-positive cell fractions were then sorted with
a FACSAria (BD Biosciences, CA, USA). The purity of the
fractions routinely exceeded 95%.
Co-immunoprecipitation and Western blotting
Cells were washed three times with cold PBS, lysed
using NP40 cell lysis buffer (Invitrogen, CA, USA), and
clarified by centrifugation at 13,000 × g for 10 min at 4°C.
A Dynabeads Protein A Immunoprecipitation Kit was
used for immunoprecipitation according to the product’s
protocol. Briefly, the Dynabeads were bound to anti-Hisantibody, incubated with rotation for 90 min at 4°C to
obtain a Dynabead-Ab complex, mixed with cell lysate,
and incubated overnight with rotation at 4°C. The
Dynabead-Ab-Ag complex was then washed, and elution
buffer was added to harvest the bound protein, which
was separated by SDS-PAGE. The proteins were then
transferred onto nitrocellulose membranes, which were
incubated with a 1:100–200 dilution of human monoclo-
nal antibodies against the following: CD133, pERK, and
pSRC. Immune complexes were visualized using the ECL
Western blotting detection system (Amersham, UK).
Quantitative real-time RT-PCR (ABI)
Total RNA (tRNA) was extracted using an RNeasy ex-
traction kit (Qiagen, Germany). Primers and probes were
obtained from Applied Biosystems™ (Life Technologies,
CA, USA) as Assay-on-Demand Gene Expression Products.
Real-time RT-PCR was performed following the supplier’s
directions. The PCR mixture (20 μl) contained 10 μl of 2x
TaqMan Universal PCR Master Mix, 1 μl of 20x working
stock of the gene expression assay mix, and 20 μg of tRNA.
Real-time RT-PCR was performed using a StepOne Real-
Time PCR System (Applied Biosystems, CA, USA). The
reaction was performed in triplicate for each sample.
The fluorescence of the PCR products was detected by the
same apparatus. The number of cycles for the amplification
plot to reach the threshold limit (Ct value) was used for
quantification. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as endogenous control.
DNA microarray
tRNA was extracted using an RNeasy extraction kit (Qiagen,
Germany). The cDNA was amplified, labeled, and hybrid-
ized to a 44 K Agilent 60-mer oligo microarray according to
the manufacturer’s instructions. All hybridized microarray
slides were then scanned by an Agilent scanner. Relative
hybridization intensities and background hybridization
values were calculated using Agilent Feature Extraction
Software.
Statistics
A statistical analysis was performed with the statistical
package StatView (Version 5.0, SAS Institute, Inc.) and
Excel (Microsoft, Washington). Data were compared using
Student’s t test, one-way analysis of variance, the Mann-
Whitney U test, and/or the Kruskal-Wallis test. All data
are presented as the mean ± standard deviation. Differ-
ences between means were considered to be statistically
significant at p < 0.05.
Additional files
Additional file 1: Figure S1. Examination of CD133 expression before
and after shRNA-CD133 transducted into Capan1M9 cells by flow cytometer.
Figure S2. In vivo experimental schedules of this study using nude mice.
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models. We created the lung and liver metastasis models using tail vein or
spleen implantation, respectively. In the lung metastasis model, nude mice
were sacrificed at every 4 weeks. +: Macroscopically detectable tumor lesion
in the organs, -: Undetectable tumor lesion in the organs. Figure S3. The
lung metastasis model created by the tail vein injection of Capan1M9-GFP
or shCD133M9-GFP cells into nude mice. GFP-positive spots (arrow) indicate
micrometastatic lesions in the section of the lung 12 weeks after the tail vein
injection of 1 × 105 Capan1M9-GFP cells. Immunohistochemical staining for
CK and CD133 was performed to identify micrometastatic lesions. Figure
S4. Comparison of tumor-take rates between CD133high and CD133KD cells
by subcutaneous xenograft tumor model. Figure S5. Comparison of tumor
growth curves in nude mice among the tumors generated by CD133high
and CD133KD cells by subcutaneous xenograft tumor model. Figure S6.
Comparison of four week’s tumor volumes between tumors generated by
CD133high and CD133KD cells in pancreatic orthotopic model. Figure S7.
Transduction of shRNACD133 or shRNASlug into Capan1M9 cells. mRNA ex-
pression levels of CD133 and Slug were examined after shRNA transduction
of CD133 or Slug into Capan1M9 cells (left). Fluorescent observation of GFP
after shRNA transduction into Capan1M9 cells (right). Figure S8. Validation of
Slug expression after ERK or TGF inhibitor treatment. Slug mRNA expression
was examined after ERK or TGF inhibitor (U0126 or SB431542) treatment.
Additional file 2: Table S1. DNA microarray analysis of epithelial-
mesenchymal transition (EMT)-related genes. The data represent a
comparison of EMT-related genes expressions between Capan1M9 and
shCD133M9 cells by DNA microarray. Table S2. Analysis of EMT-related
genes with the following Z scores: Z score≥ 2 and ratio ≥ 1.5 or Z
score≤ −2 and ratio ≤ 0.66.
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